Up 38% in a month, what's sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

| More on:
Five healthcare workers standing together and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Race Oncology shares have rocketed 39% in the past month, closing up another 15.74% today
  • The company has made a number of positive announcements last month which have helped boost its share price
  • The S&P/ASX 200 Health Care (ASX: XHJ) sector also provided support today, closing almost 2% higher

The Race Oncology Ltd (ASX: RAC) share price had yet another stunning day, leaving the broader index well behind.

At close of trade, the specialty pharmaceutical company's shares finished 15.74% ahead at $2.50 each. This means the company's shares have now risen more than 38% in the past month.

For context, the All Ordinaries Index (ASX: XAO) closed 0.5% lower to 6,784.3 points today and is now down more than 9% for the month.

What's driving Race Oncology shares forward?

Investors were rallying up the Race Oncology share price today amid the company's latest string of announcements, along with positive sentiment.

Last month, the company advised it was conducting a share buyback to increase shareholder value.

The board approved the purchase of up to four million Race Oncology shares, which represents 2.5% of its issued capital.

When the news broke, this led shares in the company to finish 11.24% higher on the day.

Furthermore, Race Oncology released a statement highlighting two peer-reviewed abstracts published in the scientific journal, Cancer Research.

Both publications noted the company's new preclinical data on the anti-cancer uses of its lead candidate Zantrene.

Again, when Race Oncology provided the update to the ASX, its shares soared 10% before market close.

After that, there was another rush on the company's shares following successful results from its Zantrene trial.

The clinical data showed that the anti-cancer drug protected the hearts of mice from chemotherapy damage.

This is particularly significant as the company is seeking to capture the "large commercial opportunity" that's present for Zantrene.

Lastly, helping the accent of Race Oncology shares is the S&P/ASX 200 Health Care (ASX: XHJ) sector advancing 1.97% today.

About the Race Oncology share price

Despite the strong gains made over the month, the Race Oncology share price is down 30% in 2022.

This is due to extreme market volatility impacting ASX shares amid rampant inflation, interest rate hikes, and a downbeat economic outlook.

Based on today's price, Race commands a market capitalisation of around $398 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »